Keenova to Present New Data on Peyronie’s Disease Treatments

The presentations will highlight real-world outcomes and clinical studies supporting the use of XIAFLEX (collagenase clostridium histolyticum) for men suffering from Peyronie’s disease, including those experiencing ventral curvature. These findings aim to provide physicians with robust evidence for managing the condition without surgical intervention.

Beyond clinical data, Keenova is introducing the Men’s Sexual Health Screener. This resource is designed to simplify how clinicians assess and discuss sensitive health concerns, addressing a significant barrier to care. According to Jesse Mills, MD, Clinical Professor at UCLA Health, providing practical tools is essential for helping clinicians identify patient needs and guide informed treatment decisions. Peyronie’s disease is estimated to affect one in 10 men in the United States, yet diagnosis rates remain low as many patients feel uncomfortable seeking help for the condition.